Search Results - "Rigoreau, L"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate by Khanim, F, Davies, N, Veliça, P, Hayden, R, Ride, J, Pararasa, C, Chong, M G, Gunther, U, Veerapen, N, Winn, P, Farmer, R, Trivier, E, Rigoreau, L, Drayson, M, Bunce, C

    Published in British journal of cancer (18-03-2014)
    “…Background: We and others have identified the aldo-keto reductase AKR1C3 as a potential drug target in prostate cancer, breast cancer and leukaemia. As a…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries by Leahy, Justin J.J., Golding, Bernard T., Griffin, Roger J., Hardcastle, Ian R., Richardson, Caroline, Rigoreau, Laurent, Smith, Graeme C.M.

    Published in Bioorganic & medicinal chemistry letters (20-12-2004)
    “…A solution-phase multiple-parallel synthesis approach was employed for the preparation of 6-, 7- and 8-aryl-substituted chromenone libraries, which were…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6